MX2023006591A - Composiciones y metodos para el tratamiento de enfermedades oculares. - Google Patents

Composiciones y metodos para el tratamiento de enfermedades oculares.

Info

Publication number
MX2023006591A
MX2023006591A MX2023006591A MX2023006591A MX2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A
Authority
MX
Mexico
Prior art keywords
compositions
methods
ocular diseases
treating ocular
age
Prior art date
Application number
MX2023006591A
Other languages
English (en)
Inventor
Ted Yednock
Anita Grover
Lori Taylor
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of MX2023006591A publication Critical patent/MX2023006591A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere en general a composiciones y métodos para prevenir, tratar o reducir el riesgo de desarrollar una enfermedad ocular (p. ej., glaucoma o degeneración macular asociada con la edad). La degeneración macular asociada con la edad puede ser atrofia geográfica.
MX2023006591A 2020-12-04 2021-12-03 Composiciones y metodos para el tratamiento de enfermedades oculares. MX2023006591A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063121629P 2020-12-04 2020-12-04
PCT/US2021/061755 WO2022120137A1 (en) 2020-12-04 2021-12-03 Compositions and methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
MX2023006591A true MX2023006591A (es) 2023-08-11

Family

ID=81853584

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006591A MX2023006591A (es) 2020-12-04 2021-12-03 Composiciones y metodos para el tratamiento de enfermedades oculares.

Country Status (11)

Country Link
US (1) US20240059765A1 (es)
EP (1) EP4255485A1 (es)
JP (1) JP2023551734A (es)
KR (1) KR20230117192A (es)
CN (1) CN116782940A (es)
AU (1) AU2021391800A1 (es)
CA (1) CA3200976A1 (es)
CL (1) CL2023001596A1 (es)
IL (1) IL303289A (es)
MX (1) MX2023006591A (es)
WO (1) WO2022120137A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3019240T3 (fi) 2013-07-09 2024-05-30 Annexon Inc Anti-komplementtitekijä c1q -vasta-aineita ja niiden käyttöjä
IL296130A (en) 2015-11-24 2022-11-01 Annexon Inc Anti-complement factor c1q fab fragments and their uses
WO2023212719A1 (en) * 2022-04-29 2023-11-02 Annexon, Inc. Compositions and methods for treating ocular diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296130A (en) * 2015-11-24 2022-11-01 Annexon Inc Anti-complement factor c1q fab fragments and their uses

Also Published As

Publication number Publication date
WO2022120137A1 (en) 2022-06-09
IL303289A (en) 2023-07-01
JP2023551734A (ja) 2023-12-12
CN116782940A (zh) 2023-09-19
EP4255485A1 (en) 2023-10-11
US20240059765A1 (en) 2024-02-22
CL2023001596A1 (es) 2024-01-19
KR20230117192A (ko) 2023-08-07
CA3200976A1 (en) 2022-06-09
AU2021391800A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
MX2023006591A (es) Composiciones y metodos para el tratamiento de enfermedades oculares.
MX2021005518A (es) Modelos animales, métodos de detección y métodos de tratamiento para enfermedades o trastornos intraoculares.
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
WO2007089375A3 (en) Compositions and methods for regulating complement system
PH12020551766A1 (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
TW200733964A (en) (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions
EP1610722A4 (en) APPARATUS FOR RE-ESTABLISHING VALVULAR AORTIC FUNCTION AND METHOD OF TREATMENT USING THE SAME
MX351152B (es) Compstatina y analogos de la misma para tratar trastornos oculares.
MX2010002617A (es) Implantes lagrimales y metodos relacionados.
AU2018218696B2 (en) Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid
EA201790889A1 (ru) Офтальмологический раствор
WO2019195761A3 (en) Pharmacological agents for treating ocular diseases
MX2022012692A (es) Composiciones que comprenden nanoparticulas, metodo de elaboracion y usos de las mismas.
WO2007130364A3 (en) Compositions, methods, and kits for treating dry eye
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
PE20220384A1 (es) Composiciones y metodos de oximetazolina para el tratamiento de trastornos oculares
MX2019012012A (es) Metodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3.
MX2021014682A (es) Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos.
EA201001326A1 (ru) Стерильные офтальмологические композиции и способ их получения
WO2008048675A3 (en) Treatment for age-related macular degeneration and other diseases of the eye
MX2013001870A (es) Formulaciones oftalmicas de escualamina.
WO2008152507A3 (en) Compositions and methods for treating ophthalmic disorders
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
MX2022002443A (es) Compuestos inhibidores de perk.
WO2019090010A3 (en) Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma